OverviewSuggest Edit

Synlogic is a biopharmaceutical company that focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases. The Company was formed as a result of a reverse merger between Mirna Therapeutics and Synlogic. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The Сompany is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors.

TypePublic
Founded2013
HQCambridge, US
Websitesynlogictx.com

Latest Updates

Employees (est.) (Mar 2019)74(+18%)
Job Openings8
Revenue (FY, 2019)$2.2 M(-11%)
Share Price (Nov 2020)$2.1
Cybersecurity ratingBMore

Key People/Management at Synlogic

Peter Barrett

Peter Barrett

Chairman
Aoife M. Brennan

Aoife M. Brennan

President, Chief Executive Officer & Director
Chau Q. Khuong

Chau Q. Khuong

Director
Gregg Beloff

Gregg Beloff

Interim Chief Financial Officer
Mike Burgess

Mike Burgess

Director
Nick Leschly

Nick Leschly

Director
Show more

Synlogic Office Locations

Synlogic has an office in Cambridge
Cambridge, US (HQ)
301 Binney St #402Cambridge
Show all (1)

Synlogic Financials and Metrics

Synlogic Revenue

Synlogic's revenue was reported to be $2.22 m in FY, 2019
USD

Net income (Q3, 2020)

(13.2m)

EBIT (Q3, 2020)

(13.4m)

Market capitalization (20-Nov-2020)

72.5m

Closing stock price (20-Nov-2020)

2.1

Cash (30-Sept-2020)

26.8m

EV

69.0m
Synlogic's current market capitalization is $72.5 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

2.4m2.5m2.2m

General and administrative expense

6.1m8.1m12.9m15.7m14.7m

R&D expense

18.9m13.9m30.3m38.0m41.9m

Operating expense total

25.0m26.5m43.3m53.8m56.6m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

111.0k354.0k254.0k1.8m338.0k350.0k305.0k100.0k445.0k

General and administrative expense

1.6m2.1m2.0m1.9m2.3m4.2m3.2m3.6m4.7m3.4m3.7m3.7m3.9m3.8m3.5m3.0m

R&D expense

4.7m4.5m3.7m3.4m242.0k5.1m9.0m8.4m10.9m9.9m10.4m9.7m10.6m12.7m12.9m10.5m

Operating expense total

6.2m6.7m5.7m5.3m5.1m9.5m12.2m12.0m15.6m13.3m14.0m13.4m14.4m16.5m16.4m13.4m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

89.7m16.4m58.4m11.3m26.2m

Prepaid Expenses

1.6m1.6m13.7m

Inventories

793.0k882.0k

Current Assets

90.5m61.4m88.6m124.3m133.2m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

35.7m52.9m30.8m27.0m17.1m15.2m79.2m27.2m26.6m17.3m15.7m17.4m27.5m19.5m31.4m26.8m

Accounts Receivable

2.0m2.5m

Prepaid Expenses

303.0k818.0k620.0k387.0k1.7m2.1m2.1m1.4m1.5m31.4m10.5m13.2m13.1m8.7m

Current Assets

36.1m81.6m73.5m67.1m58.1m48.1m98.2m127.9m145.3m136.0m113.8m162.9m131.3m127.4m122.2m110.6m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(25.0m)(26.3m)(40.4m)(48.4m)(51.4m)

Depreciation and Amortization

54.0k159.0k2.3m2.4m2.7m

Inventories

793.0k107.0k

Accounts Payable

3.7m(3.3m)4.1m(257.0k)(935.0k)
USDQ3, 2015

Financial Leverage

-0.6 x
Show all financial metrics

Synlogic Operating Metrics

FY, 2016

Patents Issued

10

Patents Pending

42
Show all operating metrics

Synlogic Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Synlogic Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Synlogic Online and Social Media Presence

Embed Graph

Synlogic News and Updates

Synlogic Initiates Phase 1 Study of SYNB8802 for the Treatment of Enteric Hyperoxaluria

CAMBRIDGE, Mass., Nov. 4, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced it has treated the first healthy volunteer in its Phase 1 study of the investigational Synthetic...

Synlogic Announces Second Quarter 2020 Conference Call & Webcast

CAMBRIDGE, Mass., July 28, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its second quarter 2020 financial results before the market opens on...

Synlogic Announces Termination of AbbVie Collaboration Agreement

CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the termination of its collaboration with AbbVie, a global, research-based...

Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities

CAMBRIDGE, Mass., March 30, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines called Synthetic Biotic™ medicines, today provided an update on its business operations and...

Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

CAMBRIDGE, Mass., March 12, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial results for the fourth quarter and full year ended December 31, 2019....

Synlogic Appoints Dr. Michael Burgess to its Board of Directors

CAMBRIDGE, Mass., Jan. 30, 2020 /PRNewswire/ -- Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Michael Burgess, M.B., Ch.B., Ph.D., president of research and...
Show more

Synlogic Frequently Asked Questions

  • When was Synlogic founded?

    Synlogic was founded in 2013.

  • Who are Synlogic key executives?

    Synlogic's key executives are Peter Barrett, Aoife M. Brennan and Chau Q. Khuong.

  • How many employees does Synlogic have?

    Synlogic has 74 employees.

  • What is Synlogic revenue?

    Latest Synlogic annual revenue is $2.2 m.

  • What is Synlogic revenue per employee?

    Latest Synlogic revenue per employee is $30.1 k.

  • Who are Synlogic competitors?

    Competitors of Synlogic include Pandion Therapeutics, Rubius Therapeutics and Bicycle Therapeutics.

  • Where is Synlogic headquarters?

    Synlogic headquarters is located at 301 Binney St #402Cambridge, Cambridge.

  • Where are Synlogic offices?

    Synlogic has an office in Cambridge.

  • How many offices does Synlogic have?

    Synlogic has 1 office.